The use of systemic and topical fluoroquinolones

Pediatrics

Volumn 138, Issue 5, 2016, Pages

  Jackson, Mary Anne ^a   Schutze, Gordon E ^a   Byington, Carrie L ^a   Maldonado, Yvonne A ^a   Barnett, Elizabeth D ^a   Campbell, James D ^a   Davies, H Dele ^a   Lynfield, Ruth ^a   Munoz, Flor M ^a   Nolt, Dawn ^a   Nyquist, Ann Christine ^a   O'Leary, Sean ^a   Rathore, Mobeen H ^a   Sawyer, Mark H ^a   Steinbach, William J ^a   Tan, Tina Q ^a   Zaoutis, Theoklis E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ACUTE OTITIS MEDIA; ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; CARDIOTOXICITY; CONJUNCTIVITIS; CRYSTAL NEPHROPATHY; DISEASE MODEL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG USE; ESCHERICHIA COLI; EXTERNAL OTITIS; FOLLOW UP; GAIT DISORDER; GASTROINTESTINAL INFECTION; HALLUCINATION; HEADACHE; HIP PAIN; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTERSTITIAL NEPHRITIS; JOINT LAXITY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOBACTERIOSIS; NAUSEA; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PERIPHERAL NEUROPATHY; PLAGUE; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK BENEFIT ANALYSIS; SCOLIOSIS; SEIZURE; SHOULDER PAIN; SINUSITIS; SLEEP DISORDER; SPINAL PAIN; TENDINITIS; TENDON DISEASE; TREATMENT DURATION; TYMPANOSTOMY TUBE OTORRHEA; URINARY TRACT INFECTION; VOMITING; AGE; BACTERIAL INFECTIONS; CHILD; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; MALE; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; PRESCHOOL CHILD; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGE FACTORS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; PATIENT SAFETY; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84994885383     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-2706     Document Type: Article

References (75)

1. Tatsumi H, Senda H, Yatera S, Takemoto Y, Yamayoshi M, Ohnishi K. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci. 1978; 3(4): 357-367
2. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979; 51(1): 177-187
3. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics. 2006; 118(3): 1287-1292
4. Bradley JS, Jackson MA; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2011; 128(4). Available at: www.pediatrics.org/cgi/content/full/128/4/e1034
5. Patterson DR Quinolone toxicity: methods of assessment. Am J Med. 1991; 91(6A): 35S-37S
6. Riecke K, Lozo E, ShakiBaei M, et al. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; September 17-20, 2000
7. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009; 33(3): 194-200
8. US Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products. Summary of clinical review of studies submitted in a response to a pediatric written request: ciprofloxacin. Available at: www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm447421.pdf. Accessed January 13, 2016
9. von Keutz E, Rühl-Fehlert C, Drommer W, Rosenbruch M. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004; 78(7): 418-424
10. US Food and Drug Administration, Division of Anti-Infective Drug Products. Review and evaluation of pharmacology and toxicology data: HFD-520. Available at: www.accessdata.fda.gov/drugsatfda-docs/nda/96/020634-3.pdf. Accessed June 30, 2010
11. Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 2009; 29(2): 189-195
12. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011; 96(9): 874-880
13. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007; 26(10): 879-891
14. Bradley JS, Kauffman RE, Balis DA, et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014; 134(1). Available at: www.pediatrics.org/cgi/content/full/134/1/e146
15. Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol. 1996; 23(3): 516-520
16. Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007; 26(10): 868-878
17. Noel GJ, Blumer JL, Pichichero ME, et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2008; 27(6): 483-489
18. Hooper DC Mechanisms of quinolone resistance. In: Hooper DC, Rubenstein E, eds. Quinolone Antimicrobial Agents. 3rd ed. Washington, DC: American Society for Microbiology Press; 2003: 41-67
19. Vien TM, Minh NNQ, Thuong TC, et al. The co-selection of fluoroquinolone resistance genes in the gut flora of Vietnamese children. PLoS One. 2012; 7(8): e42919
20. Davies TA, Leibovitz E, Noel GJ, McNeeley DF, Bush K, Dagan R. Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin. Antimicrob Agents Chemother. 2008; 52(1): 378-381
21. Mesaros N, Nordmann P, Plésiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007; 13(6): 560-578
22. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ; EMERGEncy ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008; 47(9): 1150-1158
23. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008; 121(10): 876-884
24. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in Escherichia coli from >17, 000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis. 2008; 8: 4
25. Qin X, Razia Y, Johnson JR, et al. Ciprofloxacin-resistant gram-negative bacilli in the fecal microflora of children. Antimicrob Agents Chemother. 2006; 50(10): 3325-3329
26. Adam HJ, Baxter MR, Davidson RJ, et al.; Canadian Antimicrobial Resistance Alliance. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013; 68(suppl 1): i31-i37
27. Raidt L, Idelevich EA, Dübbers A, et al. Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade. Pediatr Infect Dis J. 2015; 34(7): 700-705
28. Rose L, Coulter MM, Chan S, Hossain J, Di Pentima MC The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children. Pediatr Infect Dis J. 2014; 33(6): e158-e161
29. Tamma PD, Robinson GL, Gerber JS, et al. Pediatric antimicrobial susceptibility trends across the United States. Infect Control Hosp Epidemiol. 2013; 34(12): 1244-1251
30. Schutze GE, Willoughby RE; Committee on Infectious Diseases. Clostridium difficile infection in infants and children. Pediatrics. 2013; 131(1): 196-200
31. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013; 68(9): 1951-1961
32. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014; 69(4): 881-891
33. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011; 120(2): 103-110
34. Abo-Salem E, Fowler JC, Attari M, et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther. 2014; 32(1): 19-25
35. Torkildsen G, Proksch JW, Shapiro A, Lynch SK, Comstock TL. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin Ophthalmol. 2010; 4: 331-341
36. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005; 123(9): 1282-1283
37. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs. 2010; 12(2): 105-112
38. Kaushik V, Malik T, Saeed SR. Interventions for acute otitis externa. Cochrane Database Syst Rev. 2010; 1: CD004740
39. Granath A, Rynnel-Dagöö B, Backheden M, Lindberg K. Tube associated otorrhea in children with recurrent acute otitis media: results of a prospective randomized study on bacteriology and topical treatment with or without systemic antibiotics. Int J Pediatr Otorhinolaryngol. 2008; 72(8): 1225-1233
40. Rosenfeld RM, Singer M, Wasserman JM, Stinnett SS. Systematic review of topical antimicrobial therapy for acute otitis externa. Otolaryngol Head Neck Surg. 2006; 134(4 suppl): S24-S48
41. Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2014; 150(1 suppl): S1-S24
42. Mösges R, Nematian-Samani M, Hellmich M, Shah-Hosseini K. A meta-analysis of the efficacy of quinolone containing otics in comparison to antibiotic-steroid combination drugs in the local treatment of otitis externa. Curr Med Res Opin. 2011; 27(10): 2053-2060
43. Schwartz RH Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. Curr Med Res Opin. 2006; 22(9): 1725-1736
44. Bradley JS, Byington CL, Shah SS, et al.; Pediatric Infectious Diseases Society; Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011; 53(7): e25-e76
45. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media [published correction appears in Pediatrics. 2014; 133(2): 346]. Pediatrics. 2013; 131(3). Available at: www.pediatrics.org/cgi/content/full/131/3/e964
46. Wald ER, Applegate KE, Bordley C, et al.; American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013; 132(1). Available at: www.pediatrics.org/cgi/content/full/132/1/e262
47. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol. 2005; 45(2): 153-160
48. Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2006; 25(12): 1102-1109
49. Richter SS, Heilmann K P, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. 2005; 40(2): 225-235
50. Factive (gemifloxacin mesylate) [package insert]. Oscient Pharmaceuticals. 2008. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8345. Accessed July 6, 2015
51. Avelox (moxifloxacin hydrochloride) [package insert]. Schering Plough Corporation. 2015. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56b4f979-bf20-4908-9d7c-5536221d77f8. Accessed July 6, 2015
52. Levaquin (levofloxacin) [package insert]. Major Pharmaceuticals. 2013. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=449ddc89-6dff-4e3e-a480-66b68389c73d. Accessed July 6, 2015
53. Mandell LA, Wunderink RG, Anzueto A, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(suppl 2): S27-S72
54. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002; 346(10): 747-750
55. Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis. 2006; 42(4): 525-532
56. Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. Ann Pharmacother. 2000; 34(3): 347-359; quiz: 413-414
57. Qamar FN, Azmatullah A, Kazi AM, Khan E, Zaidi AK. A three-year review of antimicrobial resistance of Salmonella enterica serovars Typhi and Paratyphi A in Pakistan. J Infect Dev Ctries. 2014; 8(8): 981-986
58. Khanam F, Sayeed MA, Choudhury FK, et al. Typhoid fever in young children in Bangladesh: clinical findings, antibiotic susceptibility pattern and immune responses. PLoS Negl Trop Dis. 2015; 9(4): e0003619
59. Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J. 2000; 19(11): 1060-1067
60. Scallan E, Mahon BE, Hoekstra RM, Griffin PM. Estimates of illnesses, hospitalizations and deaths caused by major bacterial enteric pathogens in young children in the United States. Pediatr Infect Dis J. 2013; 32(3): 217-221
61. Centers for Disease Control and Prevention. Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers-Kansas, Kentucky, and Missouri, 2005. MMWR Morb Mortal Wkly Rep. 2006; 55(39): 1068-1071
62. Gu B, Cao Y, Pan S, et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. Int J Antimicrob Agents. 2012; 40(1): 9-17
63. Bowen A, Hurd J, Hoover C, et al.; Centers for Disease Control and Prevention. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin-United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(12): 318-320
64. Ricotta EE, Palmer A, Wymore K, et al. Epidemiology and antimicrobial resistance of international travel-associated Campylobacter infections in the United States, 2005-2011. Am J Public Health. 2014; 104(7): e108-e114
65. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003; 52(RR-11): 1-77
66. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008; 359(6): 563-574
67. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(6): 449-456
68. Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis. 2013; 17(5): 624-629
69. Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinb). 2015; 95(3): 229-245
70. Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis. 2015; 60(11): 1642-1649
71. Bradley JS, Peacock G, Krug SE, et al.; Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014; 133(5). Available at: www.pediatrics.org/cgi/content/full/133/5/e1411
72. Centers for Disease Control and Prevention. Plague. Available at: www.cdc.gov/plague/healthcare/clinicians.html. Accessed July 6, 2015
73. Inglesby TV, Dennis DT, Henderson DA, et al Plague as a biological weapon: medical and public health management. JAMA. 2000; 283(17): 2281-2290
74. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011; 55(7): 3244-3253
75. Sung L, Manji A, Beyene J, et al. Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials. Pediatr Infect Dis J. 2012; 31(5): 431-435